AMS Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

AMS Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-232,905	Closed	-$19.3M	–	16
2022 Q4	$19.3M	Hold	232,905	–	–	15.31%	3
2022 Q3	$19.1M	Hold	232,905	–	–	12.07%	4
2022 Q2	$17.3M	Hold	232,905	–	–	9.14%	3
2022 Q1	$20.9M	Hold	232,905	–	–	7.89%	3
2021 Q4	$26.1M	Buy	232,905 +53,090	+30%	+$6.4M	5.83%	6
2021 Q3	$22.6M	Hold	179,815	–	–	4.76%	5
2021 Q2	$24.3M	Buy	179,815 +59,015	+49%	+$7.76M	3.47%	8
2021 Q1	$16.4M	Buy	+120,800	New	+$18.1M	2.59%	15

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

AMS Capital's XBI Position: Q1 2023 in Review

AMS Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 232,905 shares — an estimated $19.3M sold.

AMS Capital first reported a position in XBI in Q1 2021 and held it in 8 quarters. The position peaked at $26.1M in Q4 2021. 713 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

AMS Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
AMS Capital sold 232,905 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $19.3M.
AMS Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and held it in 8 quarters.
AMS Capital's State Street SPDR S&P Biotech ETF position peaked at $26.1M in Q4 2021.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on AMS Capital's 13F filing for Q1 2023, filed 8 May 2023.